Rates and Pattern of Antifracture Drug Use in 6475 Adults and Children With Osteogenesis Imperfecta
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgaf514 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Winnie Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR 97239, USA. Hauptthemen laut MEDLINE: Osteogenesis Imperfecta, Bone Density Conservation Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: NIAMS NIH HHS, Osteogenesis Imperfecta Foundation and NIAMS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Context
Osteogenesis imperfecta (OI) is a genetic disorder characterized by increased bone fragility. Despite this, the use of antifracture drugs (AFD) among people with OI in the United States is not known.
Objective
This study examined the rates and types of AFD use in OI and whether use patterns varied with age, sex, and clinical severity.
Methods
We conducted a cohort study using medical and prescription claims data from January 1, 2011, to December 31, 2022, in MarketScan and from January 1, 2006, to December 31, 2021, in a 5% Medicare sample. Durable medical equipment claims for long-term wheelchair were used to define severe OI. Each individual with OI was matched to 5 reference patients within the same database by year of birth, sex, race, index year, and baseline enrollment duration.
Results
We identified 6494 people with OI and 32,470 individuals. The median [interquartile range] age was 21 years [8-43]. Adults comprised 55.8% of cohort; 57.6% were female. AFD use was 25.9% in the overall OI cohort and was higher in the severe OI group than in the milder group (38.3% vs 22.9%, respectively; standard mean difference 0.34). Use was highest in children, was much lower in young adults, and rose gradually with increasing age. Bisphosphonates were the most prescribed AFD across all age groups and OI severity levels.
Conclusion
These findings suggest that AFDs drugs are underutilized in the general US population of adults and children with OI. Our observed rates are lower than those reported in other studies, likely because our cohort reflects individuals in the general community rather than patients treated in specialized bone clinics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR 97239, USA.
- University of Alabama at Birmingham, Birmingham, AL 35294, USA.
- Foundation for Advancing Science Technology Education and Research, Hoover, AL 35244, USA.
- Department of Endocrinology, Bone and Minerals Unit, Odense University Hospital, 5000 Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark.
- KMEB, University of Southern Denmark, 5230 Odense, Denmark.
ORCID-Profile: Winnie Liu, Lars Folkestad, Eric S Orwoll
Förderung
- NIAMS NIH HHS
- Osteogenesis Imperfecta Foundation and NIAMS
Zitieren
APA
Liu, W., Zhang, J., Daigle, S., Xie, F., Liu, Y., Folkestad, L., Holladay, E., Curtis, J. R., & Orwoll, E. S. (2026). Rates and Pattern of Antifracture Drug Use in 6475 Adults and Children With Osteogenesis Imperfecta. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf514
Vancouver
Liu W, Zhang J, Daigle S, Xie F, Liu Y, Folkestad L, et al. Rates and Pattern of Antifracture Drug Use in 6475 Adults and Children With Osteogenesis Imperfecta. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf514
BibTeX
@article{Liu2026,
author = {Liu, Winnie and Zhang, Jingyi and Daigle, Shanette and Xie, Fenglong and Liu, Ye and Folkestad, Lars and Holladay, Emily and Curtis, Jeffrey R and Orwoll, Eric S},
title = {Rates and Pattern of Antifracture Drug Use in 6475 Adults and Children With Osteogenesis Imperfecta},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgaf514}
}
EUVIMED